(Q82961967)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

progressive multifocal leukoencephalopathy

18 January 2020

main subject

0 references

author name string

Hans-Peter Hartung

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

28-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

Natalizumab for multiple sclerosis

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Central nervous system infections - a potential complication of systemic immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970281-3

7 January 2021

10.1016/S1474-4422(08)70281-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19081511%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference